What is Oryzon Genomics' business?

Oryzon Genomics is a clinical-stage biopharmaceutical company focused on epigenetics. The company describes itself as a global leader in epigenetics and is developing iadademstat for AML.

What were the ALICE-2 trial results reported by Oryzon Genomics?

Oryzon Genomics reported a 100% (18/18) overall response rate, an 89% (16/18) composite complete remission rate and a 78% (14/18) complete response rate in ALICE-2. The Phase Ib trial is investigating iadademstat with azacitidine and venetoclax in newly diagnosed AML.

What did Oryzon Genomics report about genomic risk groups in ALICE-2?

Oryzon Genomics reported efficacy across genomic risk groups including TP53 and RAS pathway mutations and complex karyotypes, which it describes as adverse risk. Patients with TP53-mutated disease (2/2) attained complete response, while all patients with RAS pathway mutations (3/3) achieved complete response.

What did Oryzon Genomics report about TP53 variant allele frequency in ALICE-2?

Oryzon Genomics reported reductions in TP53 variant allele frequency in the two patients with TP53-mutated disease, from 14% to undetected and from 22% to 1%, respectively.

What did Oryzon Genomics report about survival outcomes in the ALICE-2 trial?

After a median follow-up of 8 months, median overall survival and event-free survival had not been reached. Oryzon Genomics reported estimated 12-month overall survival of 79% and estimated 12-month event-free survival of 71%.

How many ALICE-2 patients transitioned to transplantation, according to Oryzon Genomics?

Oryzon Genomics reported that 9 patients successfully transitioned to allogeneic haematopoietic cell transplantation. The company reported estimated 12-month overall survival of 88% for these patients.

What safety information did Oryzon Genomics provide for the ALICE-2 treatment combination?

Oryzon Genomics said the iadademstat-azacitidine-venetoclax combination continued to show a favourable safety profile. The company did not provide additional safety figures in the announcement.

What were the FRIDA trial results reported by Oryzon Genomics?

Oryzon Genomics reported a 67% (12/18) composite complete remission rate in the FRIDA expansion cohort at the selected pharmacological active dose. The Phase Ib trial is investigating iadademstat with gilteritinib in FLT3-mutated relapsed/refractory AML.

How many patients were enrolled in the FRIDA expansion cohort at the reported dose?

Oryzon Genomics said 23 patients had been enrolled at the selected pharmacological active dose of 75 ug iadademstat, with 18 evaluable for response.

What did Oryzon Genomics say about the safety of iadademstat with gilteritinib?

Oryzon Genomics said iadademstat plus standard-of-care treatment gilteritinib demonstrated a manageable safety profile without adding toxicity to standard-of-care treatment.

What future plans did Oryzon Genomics outline for iadademstat in AML?

Oryzon Genomics Chief Executive Officer Carlos Buesa said the company anticipated reporting final ALICE-2 data by year-end and advancing towards a potential registrational study in first-line AML by 2027, with a focus on adverse-risk populations. The company also said enrolment in ALICE-2 was continuing.

Where is Oryzon Genomics identified by ticker and ISIN in the announcement?

Oryzon Genomics identifies itself in the announcement with the ticker ORY and ISIN Code ES0167733015. The source does not specify a trading venue.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026

Published Thursday, 11 June 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Operational update
Published: Thursday, 11 June 2026
Source announcement: oryzon.com

Key figures
Measure	Figure	Period
Overall response rate (ORR)	100% (18/18)	Not stated
Composite complete remission (CRc) rate	89% (16/18)	Not stated
Complete response (CR) rate	78% (14/18)	Not stated
Estimated 12-month OS	79%	After a median follow-up of 8 months
CRc rate	67% (12/18)	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ORY) presented updated clinical data on iadademstat, a selective LSD1 inhibitor, from ALICE-2 and FRIDA in AML.

The presentation took place at the 2026 European Hematology Association (EHA) Annual Congress on June 11, 2026.
ALICE-2 reported 100% (18/18) ORR, 89% (16/18) CRc, and 78% (14/18) CR.
After 8 months’ median follow-up, median OS and EFS were not reached; estimated 12-month OS and EFS were 79% and 71%.
FRIDA enrolled 23 patients at 75 ug iadademstat; 18 were evaluable, with a 67% (12/18) CRc rate.
As enrollment continues, the company anticipates final data by year-end and advancing toward a potential registrational study in first-line AML by 2027.

ALICE-2 combined iadademstat with azacitidine and venetoclax; FRIDA combined it with gilteritinib in FLT3-mutated relapsed/refractory AML. Oryzon reported no added toxicity to standard-of-care gilteritinib.

Investor FAQs

Oryzon Genomics presented updated clinical data from the ALICE-2 and FRIDA trials of iadademstat in acute myeloid leukemia (AML) at the 2026 European Hematology Association Annual Congress. Iadademstat is described as a selective LSD1 inhibitor.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
Published: Thursday, 11 June 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…